Early Immunosuppression in Children and Adolescents with Crohn’s Disease


To date, failure of the first-line medical management of Crohn’s disease (CD) in children and adolescents has been followed by escalation treatment, with administration of immunomodulators, e.g., azathioprine, or biologics, such as infliximab (1). The most recent revision of the international guideline proposes stratification of the therapy, with selection of either accelerated step-up or primary treatment with biologics on the basis of predictors of poor outcome (POPO) (2). The objective of this study was to evaluate this concept of early immunosuppression with the aid of data from the largest registry of children and adolescents with chronic inflammatory bowel disease (IBD) in Europe.

Weiterlesen: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380838/

Kommentar verfassen

Ihre E-Mail-Adresse wird nicht veröffentlicht.